Meda Pharmaceuticals
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Meda Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count).
Meda Pharmaceuticals: 19 sponsored US clinical trials, none currently recruiting.
Meda Pharmaceuticals sponsors 19 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 19 completed. 19 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Seasonal Allergic Rhinitis, with 1 trials.
Top-decile sponsor footprint
Meda Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
19 of 19 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
19 total, page 1 of 1
Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)
NCT01915823
Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR
NCT01880840
3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis
NCT01794741
Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old
NCT01574612
A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis
NCT01018862
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
NCT00883168
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
NCT00824473
A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
NCT00740792
Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back
NCT00671879
A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back
NCT00671502
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
NCT00651118
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
NCT00660517
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
NCT00660829
A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies
NCT00719862
A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies
NCT00720278
A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis
NCT00720382
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies
NCT00712920
A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies
NCT01368445
Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis
NCT00783432
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 18 |
| Phase 4 | 1 |
Therapeutic Areas
How the Meda Pharmaceuticals archive is shaped
19 indexed studies, none listed as recruiting (0% open); 19 completed (100%).
Phase mix: 19 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Seasonal Allergic Rhinitis (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Meda Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 19 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Meda Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 19 archived trials
- Almirall, S.A. · 19 trials · 5% recruiting
- Bastyr University · 19 trials · 11% recruiting
- Church & Dwight Company · 19 trials · 0% recruiting
- Cordis US · 19 trials · 5% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Meda Pharmaceuticals page
19 registered trials is a research-attention snapshot, not an endorsement of Meda Pharmaceuticals or any single study.
- None of Meda Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Seasonal Allergic Rhinitis is the condition Meda Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Seasonal Allergic Rhinitis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Meda Pharmaceuticals pipeline card: 19 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.